



Spore Production of Toxigenic and Non-Toxigenic *Clostridium difficile* Isolates in Sub-MIC of Vancomycin, Clindamycin, and Ceftazidime

Ebrahim Rezazadeh Zarandi¹, Shahla Mansouri², Nouzar Nakhaee³, Farhad Sarafzadeh⁴ and Mohammad Moradi^{2,*}

¹Immunology of Infectious Diseases Research Center, Research Institute of Basic Medical Sciences, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

²Department of Microbiology and Virology, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran

³Department of Community Medicine, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran

⁴Department of Infectious Diseases, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran

*Corresponding author: Department of Microbiology and Virology, Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran. Tel: +98-9133431607, Email: m_moradie@yahoo.co.uk

Received 2017 July 10; Revised 2019 April 22; Accepted 2019 May 03.

Abstract

Background: The non-toxigenic variant of *Clostridium difficile* is prevalent in clinical samples. The reason for the high prevalence of these strains in the clinical diarrhea specimens has not yet been studied.

Objectives: Evaluation of spore production in non-toxigenic *C. difficile* isolates (A⁻/B⁻/CDT⁻) compared to toxigenic isolates (A⁺/B⁺/CDT⁺) in the absence and presence of antibiotics.

Methods: Minimum inhibitory concentration for bacteria was performed by the microdilution technique. About ~10⁶ bacteria from 18-hour culture were inoculated to pre-reduced media containing ½ × minimum inhibitory concentration (MIC) of vancomycin (VAN), clindamycin (CLI) and ceftazidime (CAZ). After 24, 48, and 96 hours, one milliliter of broth culture was added and heated for killing vegetative forms. One hundred microliters of appropriate dilution were cultured on Columbia blood agar in triplicate. After 72 hours, the number of viable spores was counted based on the colony forming unit.

Results: The result showed the spore production of non-toxigenic *C. difficile* isolates in free antibiotic media and ½ × MIC of antibiotics was similar to toxigenic isolates. The VAN, CLI, and CAZ inhibited spore production in non-toxigenic isolates as much as toxigenic isolates of *C. difficile*.

Conclusions: It seems the non-toxigenic *C. difficile* isolates are able to produce spores in the absence and presence of antibiotic in a similar manner to toxigenic isolates. Generally, their ability to produce toxin is lost, but they are able to remain, sporulate, and survive in hospitalized patients who receive antibiotics.

Keywords: *Clostridium difficile*, Antibiotics, Spore Production

1. Background

Sporulation is one of the important properties of *Clostridium difficile*. The bacterium is disseminated in the anaerobic condition of the colon and environment by the formation of spore and survives for a long time in harsh conditions. The spore is very important for spore-forming bacteria such as *C. difficile*. Because their infections are transferred by spores (1). *Clostridium difficile* contains several toxin-producing variants, whether may or may not be associated with the *C. difficile* antibiotic-associated diarrhea (AAD). These toxin-producing variants consist of *C. difficile* A⁺/B⁺/CDT⁻, A⁺/B⁺/CDT⁺, A⁻/B⁺/CDT⁻, A⁻/B⁺/CDT⁺, A⁺/B⁻/CDT⁻, A⁺/B⁻/CDT⁺, A⁻/B⁻/CDT⁻, and A⁻/B⁻/CDT⁺ (2, 3).

The most prevalent type of *C. difficile* in clinical samples

is the A⁺/B⁺/CDT⁻ toxin producing type (4). There is another variant, A⁻/B⁻/CDT⁻, which is common in the clinical specimens. Based on the type of sample source, geographical area, age, and detection methods vary from 42% - 50% (5, 6). This non-producing type is prevalent in the stool samples that are collected from environmental samples (30.8%) and hospitalized patients (6.5%) (7), in-patient wards (8.5 - 46%) (8-10), hospitalized infants (63%) (11), in- and out-patient infants (58% - 82%) (12) and in a neonate intensive care unit in Japan (96%) (13). Some researchers have considered them to be pathogenic forms (14), while others consider them to be non-pathogenic (5). Some investigators have mentioned these strains are helpful because common antibodies against non-pathogenic strains (A⁻/B⁻/CDT⁻) protect the individuals against infections with the toxigenic variants (15).

2. Objectives

Since the ability of spore formation must be a key property that helps the non-toxicogenic isolates to survive in the nature or clinical samples; therefore, the aim of this study is to evaluate spore production capability of non-pathogenic of *C. difficile* isolates (A⁻/B⁻/CDT⁻) compared to toxicogenic *C. difficile* (A⁺/B⁺/CDT⁺) in the absence and presence of antibiotic in the laboratory condition.

3. Methods

3.1. Bacterial Isolates

Two non-toxicogenic *C. difficile* isolates (A⁻/B⁻/CDT⁻) and one toxicogenic A⁺/B⁺/CDT⁺ were isolated from diarrhea samples (16). The *C. difficile* ATCC 9689 (A⁺/B⁺/CDT⁺) was prepared from the microbial collection of Microbiology Department of Kerman University of Medical Sciences. All isolates were confirmed by latex agglutination test as *C. difficile*. The existence of toxin genes and the ability of toxin production were confirmed by the PCR method and commercially ELISA technique, respectively (17-20). In brief, the isolates were cultured on brain heart infusion (BHI) blood (5% defibrinated sheep blood) agar at 37 °C for 24 hours in an anaerobic jar (Merck, Germany). The DNA was extracted from them by commercially kit (CinnaGen, Iran). The existence of *tcdA* and *tcdB* genes was carried by PCR method according to the previous study (20). For the ability of toxin production, the isolates were cultured in the pre-reduced medium [BHI broth (GIBCO, Scotland) supplemented with 1% yeast extract (BBL, USA) and 0.5% L-cysteine (MERCK, Germany)] for 48 hours in the anaerobic jar. The supernatants were separated by centrifuge and used for toxin production evaluation. The ability of toxin production was performed by *C. difficile* A & B ELISA kit (tgc BioMic, Germany) according to the kit's guidelines (21). This kit detects toxins (A & B) in supernatant simultaneously.

3.2. Minimum Inhibitory Concentration Determination

Minimum inhibitory concentration (MIC) of three clinical isolates and ATCC 9689 strains was performed in triplicates for (ceftazidime) CAZ, (clindamycin) CLI and (vancomycin) VAN (all Sigma, USA) by the microdilution method (22). In brief, the isolates were cultured on BHI agar supplemented with 5% defibrinated sheep blood and incubated in the anaerobic jar for 18 hours. The bacterial suspension was prepared upon 0.5 McFarland (1.5×10^8 CFU/mL) and used for inoculation to the tube containing pre-reduced medium (PRM) (control and $\frac{1}{2} \times$ MIC of VAN, CLI, and CAZ). Micro-titer plates containing $\frac{1}{2} \times$ MIC antibiotics in pre-reduced medium two-fold serially diluted were inoculated with $\sim 10^6$ colony forming unit (CFU)/mL

from fresh bacterial suspension (18-hour culture), and incubated in an anaerobic jar (23). The MIC was recorded after two days (24). The bacterial suspension preparation and inoculation to the tube with PRM were performed less than 30 minutes (25).

3.3. Culturing and Spore counting

Approximately $\sim 10^6$ CFU/mL bacteria from the suspension (1.5×10^8 CFU/mL) of 18-hour culture were inoculated to the 5 mL tubes (controls and each of the antibiotics) and incubated in anaerobic condition for 24, 48, and 96 hours at 37°C (22). At the appropriate times (24, 48, and 96 hours), one milliliter of the cultures (control medium and the media containing $\frac{1}{2} \times$ MIC) was frozen at 70°C. After one month the frozen cultures were thawed at room temperature and heated 10 minutes at 80°C to kill the vegetative form and for the spores to become pre-activated (26). After preparation of serial dilution, 100 μ L of the heated cultures were inoculated to Columbia blood agar (BBL, USA) supplemented with 5% defibrinated sheep blood. The plates were incubated under anaerobic jar for 72 hours at 37°C. According to the investigation of Aldape and colleagues, the number of viable spores was counted (27). For reducing the toxic effects of oxygen, all stages were performed in less than 15 minutes (28). All experiments were performed in triplicate.

4. Results

4.1. Minimum Inhibitory Concentration

The MIC of *C. difficile* ATCC 9689 strain and clinical isolates (toxicogenic and non-toxicogenic) isolates are shown in Table 1. All isolates and ATCC 9689 were sensitive to VAN, CLI, and CAZ (23, 29).

4.2. Control

Two clinical toxin non-producing types of *C. difficile* isolates and two toxin producing types (ATCC 9689 and a clinical isolate) started spore production within 24 hours and reached the maximum level at 48 hours. The maximum level of spore production was 6.5 Log/mL in the case of non-toxicogenic isolate. In total toxicogenic and the non-toxicogenic isolates had a similar pattern in spore production at different times (Figure 1).

4.3. Vancomycin, Clindamycin and Cefazidime

Non-toxicogenic isolates similar to toxicogenic ones (ATCC 9689 strain and clinical isolate) in the media (with $\frac{1}{2} \times$ MIC of antibiotics) started the spore production within 24 hours and continued it until 48-hour incubation. In addition, the spore production of ATCC 9689 strain did not stop at 48 hours, while continued and reached 4.3 to 6.5 Log/mL

Table 1. MIC and $\frac{1}{2} \times$ MIC of Clinical Isolates and ATCC 9689 Strain for VAN, CLI, and CAZ

<i>C. difficile</i>	Toxicogenic <i>C. difficile</i>		Non-Toxicogenic <i>C. difficile</i>	
Isolate source	ATCC 9689	Clinical	Clinical 1	Clinical 2
Toxin production type	A ⁺ /B ⁺ /CDT ⁻	A ⁺ /B ⁺ /CDT ⁻	A ⁻ /B ⁻ /CDT ⁻	A ⁻ /B ⁻ /CDT ⁻
MIC, $\mu\text{g/mL}$				
VAN	0.5 \pm 0	0.5 \pm 0	0.84 \pm 0.29	0.42 \pm 0.14
CLI	1 \pm 0	2 \pm 0	3.4 \pm 1.1	2 \pm 0
CAZ	13.4 \pm 4.6	8 \pm 0	2 \pm 0	6.7 \pm 2.3
$\frac{1}{2} \times$ MIC^a, $\mu\text{g/mL}$				
VAN	0.25	0.25	0.5	0.25
CLI	0.5	1	2	1
CAZ	8	4	1	4

Abbreviation: MIC, minimum inhibitory concentration.

^aMIC was performed in triplicate. It may differ in the three wells. Therefore, the highest concentration was selected for assays.




Figure 1. Spore production of toxicogenic and non-toxicogenic isolates of *Clostridium difficile* in the control media (without antibiotic) at 24, 48, and 96 hours




Figure 2. Spore production of toxicogenic and non-toxicogenic isolates of *Clostridium difficile* in the $\frac{1}{2} \times$ MIC of VAN at 24, 48, and 96 hours

after 48-96-hour incubation. In the $\frac{1}{2} \times$ MIC of antibiotic (VAN, CLI, and CAZ), the pattern of the spore production was similar in toxicogenic and non-toxicogenic isolates. The number of produced spores was 1.7 - 3.2, 2.3 - 3.3, and 2 - 3.5 for VAN, CLI, and CAZ, respectively. Generally, VAN, CLI, and CAZ inhibited the spore production in toxicogenic and non-toxicogenic isolates (Figures 2-4). All isolates (either toxicogenic or non-toxicogenic strains) and ATCC 9689 strain continued to spore production until 96 hours in the media containing $\frac{1}{2}$ MIC of VAN, CLI, and CAZ. While in the control, media the number of formed spores was similar to 48-hour-periods or sometimes less than 48 hours (Figures 1-4).

5. Discussion

Because of deletion, insertion, and point mutations in the regulatory genes and pathogenicity loci, non-toxicogenic isolates of *C. difficile* have lost the capability of toxin production (3, 30). However, it is noted that non-toxicogenic strains protect the individual against the infection of toxicogenic strains (31). The previous studies have mostly insisted on the investigation of spore production in the virulent and hypervirulent strains such as *C. difficile* ribotype 02, 014, 018, and 027 (32, 33). The investigation in different aspects showed the sporulation is an intrinsic and genetic property and it is related to the type of *C. difficile* (33, 34). The isolates of *C. difficile* with a high power of sporulation are more virulent and are more related to recurrent infec-




Figure 3. Spore production of toxigenic and non-toxicigenic isolates of *Clostridium difficile* in the $\frac{1}{2} \times$ MIC of CLI at 24, 48, and 96 hours




Figure 4. Spore production of toxigenic and non-toxicigenic isolates of *Clostridium difficile* in the $\frac{1}{2} \times$ MIC of CAZ at 24, 48, and 96 hours

tion (35). In our study and based on the literature, it seems the non-toxicigenic *C. difficile* isolates produce spore, similar to toxigenic isolates in the free antibiotic media and probably in their natural environment (colon). They have retained the capability of spore production.

Clostridium difficile is the most antibiotic-associated diarrhea pathogen and produces spores in the natural environment (colon) in the presence of antibiotics (36). Therefore, spore production of *C. difficile* strain in the presence of antibiotics was performed and it was shown that the antibiotics might or might not inhibit the sporulation. The VAN and fidaxomicin as the treatment choice of *C. difficile* AAD inhibit sporulation in the *C. difficile* UK14, ATCC 43255, and ATCC 9689 strains. While another choice treatment of *C. difficile* infections, metronidazole inhibits the spore production in the ATCC 9689 strain and enhances it in the

ATCC 53255 (27, 37). In this study, the VAN inhibits spore production in all of the clinical isolates (non-toxicigenic and toxigenic) and ATCC 9689 strain. The rate of decline was about 1.5 - 3 Log/mL depending on the isolates and period of incubation. The non-toxicigenic isolates and the toxigenic strains (clinical isolate and ATCC 9689) have similar behavior in the presence of VAN.

The effect of CLI and CAZ on spore production has not yet been explored. However, tigecycline as a protein inhibitor has reduced sporulation in the hypervirulent *C. difficile* ribotype 027. While it has enhanced the number of spores in ATCC 9689 strain (27). The spore production of three clinical isolates in the sub-MIC of CLI and CAZ has a similar pattern, and even more similar to VAN. The data show the CLI and CAZ inhibit the spore production in non-toxicigenic isolates in the same manner of toxigenic strains. The reason for either inhibition or reduction of the spore production in sub-MIC of antibiotic is not well understood. The previous studies impact on the expression of those genes related to sporulation (27, 37). Incidentally, the prevalence of the non-toxicigenic strain of *C. difficile* is high in the clinical samples (5, 7-12, 14). It is a good property of the non-toxicigenic strains, which still maintain the capability of sporulation. In particular, non-pathogenic strains are not only harmful but also they are considered useful.

5.1. Conclusions

In summary, the previous studies have insisted on sporulation in the hypervirulent strains. In this study, non-toxicigenic strains were evaluated and the data revealed non-toxicigenic isolates have the similar potential capability of sporulation in the absence or presence of the sub-lethal concentration of antibiotics. It was also postulated why the prevalence of non-toxicigenic isolates in diarrheal samples is high. Although these strains have lost the potential of toxin production; they have kept the ability to produce spore.

Footnotes

Authors' Contribution: Ebrahim Rezazadeh Zarandi performed the experimental work; Shahla Mansouri, Nouzar Nakhaee, and Farhad Sarafzadeh designed the research work and provided samples; and Mohammad Moradi prepared the manuscript.

Conflict of Interests: The authors declare there is no conflict of interest.

Financial Disclosure: It is not declared by the authors.

Funding/Support: The authors received financial support from Kerman University of Medical Sciences to perform this study.

References

1. Nerandzic MM, Donskey CJ. Activate to eradicate: Inhibition of *Clostridium difficile* spore outgrowth by the synergistic effects of osmotic activation and nisin. *PLoS One*. 2013;**8**(1). e54740. doi: [10.1371/journal.pone.0054740](https://doi.org/10.1371/journal.pone.0054740). [PubMed: [23349961](https://pubmed.ncbi.nlm.nih.gov/23349961/)]. [PubMed Central: [PMC3551897](https://pubmed.ncbi.nlm.nih.gov/PMC3551897/)].
2. Monot M, Eckert C, Lemire A, Hamiot A, Dubois T, Tessier C, et al. *Clostridium difficile*: New insights into the evolution of the pathogenicity locus. *Sci Rep*. 2015;**5**:15023. doi: [10.1038/srep15023](https://doi.org/10.1038/srep15023). [PubMed: [26446480](https://pubmed.ncbi.nlm.nih.gov/26446480/)]. [PubMed Central: [PMC4597214](https://pubmed.ncbi.nlm.nih.gov/PMC4597214/)].
3. Rupnik M. Heterogeneity of large clostridial toxins: Importance of *Clostridium difficile* toxinotypes. *FEMS Microbiol Rev*. 2008;**32**(3):541-55. doi: [10.1111/j.1574-6976.2008.0010.x](https://doi.org/10.1111/j.1574-6976.2008.0010.x). [PubMed: [18397287](https://pubmed.ncbi.nlm.nih.gov/18397287/)].
4. Cheng JW, Xiao M, Kudinha T, Kong F, Xu ZP, Sun LY, et al. Molecular epidemiology and antimicrobial susceptibility of clostridium difficile isolates from a University Teaching Hospital in China. *Front Microbiol*. 2016;**7**:1621. doi: [10.3389/fmicb.2016.01621](https://doi.org/10.3389/fmicb.2016.01621). [PubMed: [27799923](https://pubmed.ncbi.nlm.nih.gov/27799923/)]. [PubMed Central: [PMC5065952](https://pubmed.ncbi.nlm.nih.gov/PMC5065952/)].
5. Natarajan M, Walk ST, Young VB, Aronoff DM. A clinical and epidemiological review of non-toxicogenic *Clostridium difficile*. *Anaerobe*. 2013;**22**:1-5. doi: [10.1016/j.anaerobe.2013.05.005](https://doi.org/10.1016/j.anaerobe.2013.05.005). [PubMed: [23727391](https://pubmed.ncbi.nlm.nih.gov/23727391/)]. [PubMed Central: [PMC3729612](https://pubmed.ncbi.nlm.nih.gov/PMC3729612/)].
6. Woodcock A, Moradi M, Smillie FI, Murray CS, Burnie JP, Custovic A. *Clostridium difficile*, atopy and wheeze during the first year of life. *Pediatr Allergy Immunol*. 2002;**13**(5):357-60. doi: [10.1034/j.1399-3038.2002.01066.x](https://doi.org/10.1034/j.1399-3038.2002.01066.x). [PubMed: [12431195](https://pubmed.ncbi.nlm.nih.gov/12431195/)].
7. Janezic S, Ocepek M, Zidaric V, Rupnik M. *Clostridium difficile* genotypes other than ribotype 078 that are prevalent among human, animal and environmental isolates. *BMC Microbiol*. 2012;**12**:48. doi: [10.1186/1471-2180-12-48](https://doi.org/10.1186/1471-2180-12-48). [PubMed: [22452857](https://pubmed.ncbi.nlm.nih.gov/22452857/)]. [PubMed Central: [PMC3353227](https://pubmed.ncbi.nlm.nih.gov/PMC3353227/)].
8. Geric B, Rupnik M, Gerding DN, Grabnar M, Johnson S. Distribution of *Clostridium difficile* variant toxinotypes and strains with binary toxin genes among clinical isolates in an American Hospital. *J Med Microbiol*. 2004;**53**(Pt 9):887-94. doi: [10.1099/jmm.0.45610-0](https://doi.org/10.1099/jmm.0.45610-0). [PubMed: [15314196](https://pubmed.ncbi.nlm.nih.gov/15314196/)].
9. Walker AS, Eyre DW, Crook DW, Wilcox MH, Peto TE. Regarding "Clostridium difficile ribotype does not predict severe infection". *Clin Infect Dis*. 2013;**56**(12):1845-6. doi: [10.1093/cid/cit098](https://doi.org/10.1093/cid/cit098). [PubMed: [23420817](https://pubmed.ncbi.nlm.nih.gov/23420817/)]. [PubMed Central: [PMC3658362](https://pubmed.ncbi.nlm.nih.gov/PMC3658362/)].
10. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary symptomless colonisation by *Clostridium difficile* and decreased risk of subsequent diarrhoea. *Lancet*. 1998;**351**(9103):633-6. doi: [10.1016/S0140-6736\(97\)08062-8](https://doi.org/10.1016/S0140-6736(97)08062-8). [PubMed: [9500319](https://pubmed.ncbi.nlm.nih.gov/9500319/)].
11. Collignon A, Ticchi L, Depitre C, Gaudelus J, Delmee M, Corthier G. Heterogeneity of *Clostridium difficile* isolates from infants. *Eur J Pediatr*. 1993;**152**(4):319-22. doi: [10.1007/BF01956743](https://doi.org/10.1007/BF01956743). [PubMed: [8482281](https://pubmed.ncbi.nlm.nih.gov/8482281/)].
12. Rousseau C, Lemee L, Le Monnier A, Poilane I, Pons JL, Collignon A. Prevalence and diversity of *Clostridium difficile* strains in infants. *J Med Microbiol*. 2011;**60**(Pt 8):1112-8. doi: [10.1099/jmm.0.029736-0](https://doi.org/10.1099/jmm.0.029736-0). [PubMed: [21393454](https://pubmed.ncbi.nlm.nih.gov/21393454/)].
13. Kato H, Kato N, Watanabe K, Ueno K, Ushijima H, Hashira S, et al. Application of typing by pulsed-field gel electrophoresis to the study of *Clostridium difficile* in a neonatal intensive care unit. *J Clin Microbiol*. 1994;**32**(9):2067-70. [PubMed: [7814526](https://pubmed.ncbi.nlm.nih.gov/7814526/)]. [PubMed Central: [PMC263943](https://pubmed.ncbi.nlm.nih.gov/PMC263943/)].
14. Martirosian G, Szczesny A, Cohen SH, Silva J Jr. Isolation of non-toxicogenic strains of *Clostridium difficile* from cases of diarrhea among patients hospitalized in hematology/oncology ward. *Pol J Microbiol*. 2004;**53**(3):197-200. [PubMed: [15702921](https://pubmed.ncbi.nlm.nih.gov/15702921/)].
15. Musher DM, Koo H. Non-toxicogenic *Clostridium difficile* to prevent recurrent *C. difficile* infection. *Evid Based Med*. 2016;**21**(2):67. doi: [10.1136/ebmed-2015-110234](https://doi.org/10.1136/ebmed-2015-110234). [PubMed: [26763618](https://pubmed.ncbi.nlm.nih.gov/26763618/)].
16. Rezazadeh Zarandi E, Mansouri S, Nakhaee N, Sarafzadeh F, Iranmanesh Z, Moradi M. Frequency of antibiotic associated diarrhea caused by *Clostridium difficile* among hospitalized patients in intensive care unit, Kerman, Iran. *Gastroenterol Hepatol Bed Bench*. 2017;**10**(3):229-34. [PubMed: [29118940](https://pubmed.ncbi.nlm.nih.gov/29118940/)]. [PubMed Central: [PMC5660274](https://pubmed.ncbi.nlm.nih.gov/PMC5660274/)].
17. Braun M, Herholz C, Straub R, Choizat B, Frey J, Nicolet J, et al. Detection of the ADP-ribosyltransferase toxin gene (*cdtA*) and its activity in *Clostridium difficile* isolates from Equidae. *FEMS Microbiol Lett*. 2000;**184**(1):29-33. doi: [10.1111/j.1574-6968.2000.tb08985.x](https://doi.org/10.1111/j.1574-6968.2000.tb08985.x). [PubMed: [10689161](https://pubmed.ncbi.nlm.nih.gov/10689161/)].
18. Neff GW, Jones M, Jonas M, Ravinuthala R, Novick D, Kaiser TE, et al. Lack of *Clostridium difficile* infection in patients treated with rifaximin for hepatic encephalopathy: A retrospective analysis. *J Clin Gastroenterol*. 2013;**47**(2):188-92. doi: [10.1097/MCG.0b013e318276be13](https://doi.org/10.1097/MCG.0b013e318276be13). [PubMed: [23314671](https://pubmed.ncbi.nlm.nih.gov/23314671/)].
19. Altindis M, Usluer S, Ciftci H, Tunc N, Cetinkaya Z, Aktepe OC. Investigation of the presence of *Clostridium difficile* in antibiotic associated diarrhea patients by culture and toxin detection methods. *Mikrobiyol Bul*. 2007;**41**(1):29-37. Turkish. [PubMed: [17427550](https://pubmed.ncbi.nlm.nih.gov/17427550/)].
20. Goncalves C, Decre D, Barbut F, Burghoffer B, Petit JC. Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from *Clostridium difficile*. *J Clin Microbiol*. 2004;**42**(5):1933-9. doi: [10.1128/jcm.42.5.1933-1939.2004](https://doi.org/10.1128/jcm.42.5.1933-1939.2004). [PubMed: [15131151](https://pubmed.ncbi.nlm.nih.gov/15131151/)]. [PubMed Central: [PMC404597](https://pubmed.ncbi.nlm.nih.gov/PMC404597/)].
21. Zarandi ER, Mansouri S, Nakhaee N, Sarafzadeh F, Moradi M. Toxin production of *Clostridium difficile* in sub-MIC of vancomycin and clindamycin alone and in combination with ceftazidime. *Microb Pathog*. 2017;**107**:249-53. doi: [10.1016/j.micpath.2017.03.002](https://doi.org/10.1016/j.micpath.2017.03.002). [PubMed: [28286152](https://pubmed.ncbi.nlm.nih.gov/28286152/)].
22. Garneau JR, Valiquette L, Fortier LC. Prevention of *Clostridium difficile* spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam. *BMC Infect Dis*. 2014;**14**:29. doi: [10.1186/1471-2334-14-29](https://doi.org/10.1186/1471-2334-14-29). [PubMed: [24422950](https://pubmed.ncbi.nlm.nih.gov/24422950/)]. [PubMed Central: [PMC3897887](https://pubmed.ncbi.nlm.nih.gov/PMC3897887/)].
23. Gerber M, Walch C, Löffler B, Tischendorf K, Reischl U, Ackermann G. Effect of sub-MIC concentrations of metronidazole, vancomycin, clindamycin and linezolid on toxin gene transcription and production in *Clostridium difficile*. *J Med Microbiol*. 2008;**57**(Pt 6):776-83. doi: [10.1099/jmm.0.47739-0](https://doi.org/10.1099/jmm.0.47739-0). [PubMed: [18480337](https://pubmed.ncbi.nlm.nih.gov/18480337/)].
24. Goudarzi M, Goudarzi H, Alebouyeh M, Azimi Rad M, Shayegan Mehr FS, Zali MR, et al. Antimicrobial susceptibility of clostridium difficile clinical isolates in Iran. *Iran Red Crescent Med J*. 2013;**15**(8):704-11. doi: [10.5812/ircmj.5189](https://doi.org/10.5812/ircmj.5189). [PubMed: [24578839](https://pubmed.ncbi.nlm.nih.gov/24578839/)]. [PubMed Central: [PMC3918196](https://pubmed.ncbi.nlm.nih.gov/PMC3918196/)].
25. Pirs T, Avbersek J, Zdovc I, Krt B, Andlovic A, Lejko-Zupanc T, et al. Antimicrobial susceptibility of animal and human isolates of *Clostridium difficile* by broth microdilution. *J Med Microbiol*. 2013;**62**(Pt 9):1478-85. doi: [10.1099/jmm.0.058875-0](https://doi.org/10.1099/jmm.0.058875-0). [PubMed: [23861298](https://pubmed.ncbi.nlm.nih.gov/23861298/)].
26. Rodriguez-Palacios A, Lejeune JT. Moist-heat resistance, spore aging, and superdormancy in *Clostridium difficile*. *Appl Environ Microbiol*. 2011;**77**(9):3085-91. doi: [10.1128/AEM.01589-10](https://doi.org/10.1128/AEM.01589-10). [PubMed: [21398481](https://pubmed.ncbi.nlm.nih.gov/21398481/)]. [PubMed Central: [PMC3126382](https://pubmed.ncbi.nlm.nih.gov/PMC3126382/)].
27. Aldape MJ, Heeney DD, Bryant AE, Stevens DL. Tigecycline suppresses toxin A and B production and sporulation in *Clostridium difficile*. *J Antimicrob Chemother*. 2015;**70**(1):153-9. doi: [10.1093/jac/dku325](https://doi.org/10.1093/jac/dku325). [PubMed: [25151204](https://pubmed.ncbi.nlm.nih.gov/25151204/)]. [PubMed Central: [PMC4267498](https://pubmed.ncbi.nlm.nih.gov/PMC4267498/)].
28. Jump RL, Pultz MJ, Donskey CJ. Vegetative *Clostridium difficile* survives in room air on moist surfaces and in gastric contents with reduced acidity: A potential mechanism to explain the association between proton pump inhibitors and *C. difficile*-associated diarrhea? *Antimicrob Agents Chemother*. 2007;**51**(8):2883-7. doi: [10.1128/AAC.01443-06](https://doi.org/10.1128/AAC.01443-06). [PubMed: [17562803](https://pubmed.ncbi.nlm.nih.gov/17562803/)]. [PubMed Central: [PMC1932506](https://pubmed.ncbi.nlm.nih.gov/PMC1932506/)].
29. Nerandzic MM, Donskey CJ. Effect of ceftobiprole treatment on growth of and toxin production by *Clostridium difficile* in cecal contents of mice. *Antimicrob Agents Chemother*. 2011;**55**(5):2174-7. doi: [10.1128/AAC.01612-10](https://doi.org/10.1128/AAC.01612-10). [PubMed: [21343463](https://pubmed.ncbi.nlm.nih.gov/21343463/)]. [PubMed Central: [PMC3088227](https://pubmed.ncbi.nlm.nih.gov/PMC3088227/)].

30. Brouwer MS, Roberts AP, Hussain H, Williams RJ, Allan E, Mul-lany P. Horizontal gene transfer converts non-toxigenic Clostridium difficile strains into toxin producers. *Nat Commun.* 2013;**4**:2601. doi: [10.1038/ncomms3601](https://doi.org/10.1038/ncomms3601). [PubMed: [24131955](https://pubmed.ncbi.nlm.nih.gov/24131955/)]. [PubMed Central: [PMC3826655](https://pubmed.ncbi.nlm.nih.gov/PMC3826655/)].
31. Nagaro KJ, Phillips ST, Cheknis AK, Sambol SP, Zukowski WE, Johnson S, et al. Nontoxigenic Clostridium difficile protects hamsters against challenge with historic and epidemic strains of toxigenic BI/NAP1/027 C. difficile. *Antimicrob Agents Chemother.* 2013;**57**(11):5266–70. doi: [10.1128/AAC.00580-13](https://doi.org/10.1128/AAC.00580-13). [PubMed: [23939887](https://pubmed.ncbi.nlm.nih.gov/23939887/)]. [PubMed Central: [PMC3811292](https://pubmed.ncbi.nlm.nih.gov/PMC3811292/)].
32. Barbanti F, Spigaglia P. Characterization of Clostridium difficile PCR-ribotype 018: A problematic emerging type. *Anaerobe.* 2016;**42**:123–9. doi: [10.1016/j.anaerobe.2016.10.003](https://doi.org/10.1016/j.anaerobe.2016.10.003). [PubMed: [27725230](https://pubmed.ncbi.nlm.nih.gov/27725230/)].
33. Zidaric V, Rupnik M. Sporulation properties and antimicrobial susceptibility in endemic and rare Clostridium difficile PCR ribo-types. *Anaerobe.* 2016;**39**:183–8. doi: [10.1016/j.anaerobe.2016.04.010](https://doi.org/10.1016/j.anaerobe.2016.04.010). [PubMed: [27095618](https://pubmed.ncbi.nlm.nih.gov/27095618/)].
34. Durre P. Physiology and sporulation in Clostridium. *Microbiol Spectr.* 2014;**2**(4):TBS-10-2012. doi: [10.1128/microbiolspec.TBS-0010-2012](https://doi.org/10.1128/microbiolspec.TBS-0010-2012). [PubMed: [26104199](https://pubmed.ncbi.nlm.nih.gov/26104199/)].
35. Carlson PE Jr, Kaiser AM, McColm SA, Bauer JM, Young VB, Aronoff DM, et al. Variation in germination of Clostridium difficile clinical isolates correlates to disease severity. *Anaerobe.* 2015;**33**:64–70. doi: [10.1016/j.anaerobe.2015.02.003](https://doi.org/10.1016/j.anaerobe.2015.02.003). [PubMed: [25681667](https://pubmed.ncbi.nlm.nih.gov/25681667/)]. [PubMed Central: [PMC4467518](https://pubmed.ncbi.nlm.nih.gov/PMC4467518/)].
36. Ciricillo J, Haslam D, Blum S, Kim MO, Liu C, Paulsen G, et al. Frequency and risks associated with Clostridium difficile-associated diarrhea after pediatric solid organ transplantation: A single-center retrospective review. *Transpl Infect Dis.* 2016;**18**(5):706–13. doi: [10.1111/tid.12584](https://doi.org/10.1111/tid.12584). [PubMed: [27492796](https://pubmed.ncbi.nlm.nih.gov/27492796/)].
37. Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Sonenshein AL. Fidaxomicin inhibits spore production in Clostridium difficile. *Clin Infect Dis.* 2012;**55** Suppl 2:S162–9. doi: [10.1093/cid/cis453](https://doi.org/10.1093/cid/cis453). [PubMed: [22752866](https://pubmed.ncbi.nlm.nih.gov/22752866/)]. [PubMed Central: [PMC3388029](https://pubmed.ncbi.nlm.nih.gov/PMC3388029/)].